Following Medtronic Inc.’s (NYSE:MDT) recent announcement that it had received CE Mark (Conformité Européenne) approval for the commercial sale of the Endeavor™ Drug-Eluting Coronary Stent with the Rapid Exchange Delivery System, Medtronic Mediterranean will proudly launch the product in the Middle East.
The Endeavor system – the first cobalt alloy platform on the drug-eluting stent (DES) market – offers best-in-class deliverability, excellent clinical results and a strong patient safety profile.
“We are very pleased to provide physicians and patients with Medtronic’s high performance Endeavor drug-eluting stent system,” said Scott Ward, President of Medtronic Vascular in the United States. “Physicians will now have a broader choice among the drug-eluting stents that are available to treat their patients. We believe the Endeavor system offers a powerful combination of deliverability, efficacy and safety that is unmatched by any other commercially available stent.”
Drug-eluting stents are tiny mesh tubes coated with medicine and used to prop open arteries during angioplasty procedures. They have been proven to be superior to traditional bare-metal stents at reducing the rate of repeat procedures due to re-clogging of arteries (restenosis) in patients with coronary artery disease.
Sohail Assi, Business Manager Medtronic Vascular, for Medtronic Mediterranean which is based in Beirut, noted that Medtronic sales representatives and customer support staff are fully trained, and the company has an ample supply of Endeavor systems to support the aggressive global rollout. “Our people and our facilities are well-prepared to deliver Endeavor to physicians and patients with no delays,” Assi said.
Dr. Jean Fajadet, M.D., Clinique Pasteur Unité de Cardiologie Interventionnelle, Toulouse, France, and one of the co-principal investigators of the ENDEAVOR II pivotal trial, commented: “The results from the ENDEAVOR trials to date have been both comprehensive and positive,” said Dr. Fajadet. “I have had experience with each of the drug-coated stents on the market, and I believe that physicians in the European Union and elsewhere around the world will find that Endeavor represents an excellent course of treatment for their patients.”
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, U.S.A., is the global leader in medical technology, alleviateng pain, restoring health, and extending life for millions of people around the world. Middle East and subcontinent headquarters are in Beirut, Lebanon.
